Role reversal for large-cap medtechs
Shareholders are rewarding the kinds of companies they punished a year ago.
Covid-19 divides the biggest medtechs
Success or failure on the stock markets this year depended almost entirely on whether a company’s devices could be used to treat coronavirus patients.
Few groups have developed Covid-19 diagnostics – but this will change
The FDA is loosening its rules on the authorisation of diagnostic tests for the new coronavirus, but it is still some way behind Europe.
Led by Tandem, small-cap medtechs pump up the value in 2018
The fastest share price growth in medtech is always recorded by small-caps, but Tandem reached a new extreme last year.
Roche leaves Abbott in the dust when it comes to US approval times
The Swiss group has succeeded with its internally developed diagnostics, but buying in innovation has served Becton Dickinson well.
2017 saw the stars Align for big-cap medtech
Toothy grins all round at Align, but it is unclear how much longer it can keep up its scorching rate of sales growth.
